The side of the primary tumor affects overall survival in colon adenocarcinoma: an analysis of the national cancer database
Due to conflicting study results on the effect of laterality on overall survival in primary colon cancers, we sought to examine the impact of left compared to right-sided primary tumors on overall survival for stage I–III colon cancer using the largest dataset to date.
The 2006–2013 NCDB was queried for patients with single primary, stage I–III colon adenocarcinoma and grouped by stage and tumor location.
For stage I–II tumors, 114,839 patients had resection (62% right:38% left). After adjustment, patients with right-sided tumors had superior survival ([HR right as reference]: 1.13, 95% CI 1.09–1.17, p < 0.001). For stage III tumors, 71,024 patients had resection, (59% right:41% left). After adjustment, patients with left-sided tumors had superior survival with chemotherapy (HR 0.85, p < 0.001) and no difference in survival without chemotherapy (HR 0.97, p = 0.18).
The side of the primary tumor impacts overall survival across stages for colon adenocarcinoma. Patients with right-sided tumors have superior survival for stage I–II disease while patients with left-sided stage III disease demonstrate a survival advantage, suggesting an opportunity for investigators to use sidedness as a surrogate for prognosis and chemoresponsiveness.
KeywordsColon adenocarcinoma Overall survival Sidedness Left versus right Chemotherapy Surgery
All the authors have approved the final manuscript. MCT was responsible for concept generation, data acquisition, statistical analysis, data interpretation, manuscript writing, revisions and submission. DB was responsible for data interpretation, manuscript writing, and manuscript revisions. ZS was responsible for concept generation, data acquisition, statistical analysis, data interpretation, and manuscript revisions. KL was responsible for concept generation, data interpretation, and manuscript revisions. JW was responsible for data interpretation, manuscript writing, revisions and submission. JM was responsible for concept generation, data acquisition, data interpretation, and manuscript revisions. CRM was responsible for concept generation, data acquisition, data interpretation, and manuscript revisions. DGB was responsible for concept generation, data interpretation, and manuscript revisions and provided study oversight.
This project was performed using departmental funds and received no external funding.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
Ethics approval and consent to participate
This study was granted exempt status by the Duke Institutional Review Board given the de-identified nature of the dataset.
Informed consent was not performed in this setting.
Availability of the data and material
The data were acquired by application through the National Cancer Database (NCDB). The statistical analysis was performed in R (Vienna, Austria). The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in this study are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigators.
- 1.Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN et al (2010) Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116(3):544–573CrossRefGoogle Scholar
- 5.Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F et al (2017) Prognostic and predictive relevance of primary tumor location in patients with ras wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 3(2):194–201. https://doi.org/10.1001/jamaoncol.2016.3797 CrossRefGoogle Scholar
- 7.von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG et al (2014) Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 140(9):1607–1614CrossRefGoogle Scholar
- 8.Hansen IO, Jess P (2012) Possible better long-term survival in left versus right-sided colon cancer—a systematic review. Dan Med J 59(6):A4444Google Scholar
- 13.Nasir A, Lopez A, Boulware D, Malafa M, Coppola D (2011) Correlation between COX-2 and APC expression in left versus right-sided human colon cancer. Anticancer Res 31(6):2191–2195Google Scholar
- 15.Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ et al (2003) Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12(8):755–762Google Scholar
- 21.National Cancer Institute (US), SEER Program (National Cancer Institute (US)). Surveillance, epidemiology, and end results [unspecified]. Bethesda, Md.: The Institute. http://seer.cancer.gov/. Accessed Jan 2018
- 28.National Comprehensive Cancer Network (US) (2003) The complete library of NCCN clinical practice guidelines in oncology. Rockledge, PA: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/default.asp. Accessed Nov 2016